Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00022893
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-08-15
Brief Title:
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkins Lymphoma
Sponsor:
Corixa Corporation
Organization:
Corixa Corporation
Study Overview
Official Title:
Retreatment Study of Patients With Non-Hodgkins Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody
Status:
UNKNOWN
Status Verified Date:
2004-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkins lymphoma NHL who previously responded PR CCR or CR for at least 3 months to Iodine-131 Anti-B1 Antibody therapy
Detailed Description:
The endpoints of the study are to determine the response rate complete response rate duration of response time to progression time-to-treatment failure safety and survival following Iodine-131 Anti-B1 Antibody therapy in patients with NHL who previously responded PR CCR or CR with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None